Unlocking the potential of
genomic medicine


Aevi Genomic Medicine is focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering diseases.  More>>

There are no items to display.

Stock Quote

Recent News

More >>
Date Title and Summary
Toggle Summary07/19/2018
-FDA provisionally agreed that AEVI-004 is a co-crystal and a novel drug substance -FDA provisionally agreed existing AEVI-001 toxicology and pathology studies are acceptable to support clinical development with AEVI-004, with minimal preclinical bridging studies -AEVI-004 is expected to have
Toggle Summary06/13/2018
PHILADELPHIA , June 13, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Wednesday, June 20, 2018 at 1:00 p.m. EDT at the St.
Toggle Summary06/12/2018
- Enrollment of ASCEND trial to be increased from 42 to 64 participants - Top-line results expected during the fourth quarter 2018 PHILADELPHIA , June 12, 2018 /PRNewswire/ --   Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced that it will increase the sample size for Part A

Recent Presentations

More >>
Date Title

Upcoming Events

More >>
There are currently no events to display.

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Aevi Genomic Medicine, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Copyright Nasdaq. Minimum 15 minutes delayed.